Rallybio Corp 8-K

What Happened

• Rallybio Corporation filed an 8-K on March 2, 2026 disclosing that on March 1, 2026 it entered into an Agreement and Plan of Merger to combine with Candid Therapeutics, Inc. under which Candid will become a wholly owned subsidiary of Rallybio at closing. The deal is intended to qualify as a tax‑free reorganization for U.S. federal income tax purposes.
• Concurrent with the Merger Agreement, Candid entered into a Subscription Agreement for a Concurrent Financing of $505.5 million. Rallybio will file a Form S-4 to register the shares issued in the merger and will seek Rallybio stockholder approval for several items including issuance of shares representing more than 20% of outstanding stock, a reverse split, and a name change to “Candid Therapeutics, Inc.” Ken Song, MD (Candid’s Chairman, President & CEO) is expected to serve as President and CEO of the combined company; current Rallybio executives and directors are expected to tender resignations.

Key Details

• Merger signed: March 1, 2026; joint press release and investor materials issued March 2, 2026.
• Concurrent Financing: subscription for Candid common stock totaling $505.5 million (Investors to own ~38.80% pro forma assuming $505.5M).
• Expected pro forma ownership (assumptions noted in agreement): Candid pre‑merger equity ~57.55%, Rallybio pre‑merger equity ~3.65%, Investors ~38.80% (based on a Candid valuation of $750M and assumed Rallybio valuation of $47.5M with Rallybio Net Cash of $37.5M).
• Nasdaq and corporate housekeeping: Rallybio implemented a 1‑for‑8 reverse stock split effective Feb 6, 2026 and on Feb 24, 2026 Nasdaq notified the company it had regained compliance with the $1.00 minimum bid price rule.
• Contingent Value Rights (CVRs): Rallybio will issue CVRs to holders of certain Rallybio securities to share in potential proceeds from dispositions of Rallybio’s pre‑Merger assets (including specified Recursion Pharmaceuticals proceeds); CVR payments are uncertain and may be zero.

Why It Matters

• Control and ownership change: the transaction will materially dilute current Rallybio holders and change control of the public company if completed — issuance of post‑merger shares and the Concurrent Financing together shift majority economic ownership to Candid investors and the new Investors.
• Management and strategy: Candid’s CEO is expected to lead the combined company and Rallybio’s current executives and directors are expected to resign, signaling a strategic pivot toward Candid’s T‑cell engager autoimmune pipeline.
• Closing is not certain: the merger requires Rallybio and Candid stockholder approvals, effectiveness of the Form S‑4, receipt of financing (minimum cash conditions), Nasdaq approvals, HSR clearance and other customary conditions. Investors should note the filing’s statement that CVR holders may never receive payments and that termination fees and other protections exist for both parties.

Investors should read the Form S‑4 / Proxy Statement when filed for full details and consider the potential dilution, leadership changes, and closing risks disclosed in the 8‑K.